These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20634545)

  • 1. Decision making with regard to antiviral intervention during an influenza pandemic.
    Shim E; Chapman GB; Galvani AP
    Med Decis Making; 2010; 30(4):E64-81. PubMed ID: 20634545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiological consequences of household-based antiviral prophylaxis for pandemic influenza.
    Black AJ; House T; Keeling MJ; Ross JV
    J R Soc Interface; 2013 Apr; 10(81):20121019. PubMed ID: 23389899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the role of basic control measures, antivirals and vaccine in curtailing pandemic influenza: scenarios for the US, UK and the Netherlands.
    Nuño M; Chowell G; Gumel AB
    J R Soc Interface; 2007 Jun; 4(14):505-21. PubMed ID: 17251132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral resistance and the control of pandemic influenza.
    Lipsitch M; Cohen T; Murray M; Levin BR
    PLoS Med; 2007 Jan; 4(1):e15. PubMed ID: 17253900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral stockpiles for influenza pandemics from the household perspective: treatment alone versus treatment with prophylaxis.
    Kwok KO; Leung GM; Mak P; Riley S
    Epidemics; 2013 Jun; 5(2):92-7. PubMed ID: 23746802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic.
    Khazeni N; Hutton DW; Garber AM; Owens DK
    Ann Intern Med; 2009 Dec; 151(12):840-53. PubMed ID: 20008760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy.
    Wu JT; Leung GM; Lipsitch M; Cooper BS; Riley S
    PLoS Med; 2009 May; 6(5):e1000085. PubMed ID: 19440354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and antiviral intervention strategies for mitigating an influenza epidemic.
    Moss R; McCaw JM; McVernon J
    PLoS One; 2011 Feb; 6(2):e14505. PubMed ID: 21346794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling strategic use of the national antiviral stockpile during the CONTAIN and SUSTAIN phases of an Australian pandemic influenza response.
    McVernon J; McCaw JM; Nolan TM
    Aust N Z J Public Health; 2010 Apr; 34(2):113-9. PubMed ID: 23331352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating antiviral effectiveness against pandemic influenza using household data.
    Glass K; Becker NG
    J R Soc Interface; 2009 Aug; 6(37):695-703. PubMed ID: 19064345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-prioritized use of antivirals during an influenza pandemic.
    Merler S; Ajelli M; Rizzo C
    BMC Infect Dis; 2009 Jul; 9():117. PubMed ID: 19638194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of prophylaxis of healthcare workers on influenza pandemic burden.
    Gardam M; Liang D; Moghadas SM; Wu J; Zeng Q; Zhu H
    J R Soc Interface; 2007 Aug; 4(15):727-34. PubMed ID: 17360253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs.
    Lugnér AK; Postma MJ
    Eur J Public Health; 2009 Oct; 19(5):516-20. PubMed ID: 19692550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of antiviral drugs in containing pandemic influenza. Contribution of recent modelling exercises synthesis prepared by the InVS/Inserm "epidemiology" group - November 2005].
    Lévy-Bruhl D
    Med Mal Infect; 2006 Sep; 36(9):449-53. PubMed ID: 17027218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral agents for influenza: a comparison of cost-effectiveness data.
    Lynd LD; Goeree R; O'Brien BJ
    Pharmacoeconomics; 2005; 23(11):1083-106. PubMed ID: 16277546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using a Dynamic Model to Consider Optimal Antiviral Stockpile Size in the Face of Pandemic Influenza Uncertainty.
    Greer AL; Schanzer D
    PLoS One; 2013; 8(6):e67253. PubMed ID: 23805303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To test or to treat? An analysis of influenza testing and antiviral treatment strategies using economic computer modeling.
    Lee BY; McGlone SM; Bailey RR; Wiringa AE; Zimmer SM; Smith KJ; Zimmerman RK
    PLoS One; 2010 Jun; 5(6):e11284. PubMed ID: 20585642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drivers and consequences of influenza antiviral resistant-strain emergence in a capacity-constrained pandemic response.
    Dafilis MP; Moss R; McVernon J; McCaw J
    Epidemics; 2012 Dec; 4(4):219-26. PubMed ID: 23351374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.
    Turner D; Wailoo A; Nicholson K; Cooper N; Sutton A; Abrams K
    Health Technol Assess; 2003; 7(35):iii-iv, xi-xiii, 1-170. PubMed ID: 14609480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the use of oseltamivir prophylaxis in the control of influenza outbreaks in long-term care facilities in Alberta, Canada: a retrospective provincial database analysis.
    Ye M; Jacobs A; Khan MN; Jaipaul J; Oda J; Johnson M; Doroshenko A
    BMJ Open; 2016 Jul; 6(7):e011686. PubMed ID: 27381211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.